Envestnet Asset Management
SCNI

Envestnet Asset Management’s Scinai Immunotherapeutics SCNI Stock Holding History

Envestnet Asset Management’s Portfolio SCNI Stock Details SCNI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-79
Closed -$58K – 4045
2022
Q3 		$58K Sell
79
-84
-52% -$94.5K ﹤0.01% 3798
2022
Q2 		$191K Buy
163
+113
+226% +$155K ﹤0.01% 3616
2022
Q1 		$83K Hold
50
– – ﹤0.01% 3824
2021
Q4 		$118K Buy
+50
New +$103K ﹤0.01% 3743

Other funds holding SCNI

SM
Sabby Management Miami Beach, Florida $111M AUM 74.4% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Credit Agricole
Credit Agricole Montrouge Cedex, France $49.3B AUM 36.45% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $672B AUM 33.48% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
APC
Aspire Private Capital Cornelius, North Carolina $484M AUM 17.28% 1-Year Est. Return
GRP
Global Retirement Partners San Rafael, California $6.54B AUM
Wells Fargo
Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return
NC
NewSquare Capital Newtown Square, Pennsylvania $1.35B AUM 34.37% 1-Year Est. Return

Envestnet Asset Management's SCNI Position: Q4 2022 in Review

Envestnet Asset Management sold out of Scinai Immunotherapeutics (SCNI) in Q4 2022, closing a stake of 79 shares — an estimated $58K sold.

Envestnet Asset Management first reported a position in SCNI in Q4 2021 and held it in 4 quarters. The position peaked at $191K in Q2 2022. 8 funds tracked by Wall St. Rank hold SCNI as of Q4 2022.

  • Envestnet Asset Management reported no remaining Scinai Immunotherapeutics position as of Q4 2022 after selling out during the quarter.
  • Envestnet Asset Management sold 79 Scinai Immunotherapeutics shares in Q4 2022, an estimated $58K.
  • Envestnet Asset Management first reported a position in Scinai Immunotherapeutics in Q4 2021 and held it in 4 quarters.
  • Envestnet Asset Management's Scinai Immunotherapeutics position peaked at $191K in Q2 2022.
  • 8 funds tracked by Wall St. Rank held Scinai Immunotherapeutics as of Q4 2022.

Based on Envestnet Asset Management's 13F filing for Q4 2022, filed 7 Feb 2023.